To compare the TYK2-specific (Bayer-18 or TYK2) and the pan-JAK inhibitor, JAK inhibitor 1 or Ruxolitinib, we treated ALCL cells for 3 h, and then stimulated the cells for 10 min with Interferon-alpha (IFN-α), which is known to induce TYK2 and JAK1 activity [1, 27]. This evidence concerns the gene JAK1 and anaplastic large cell lymphoma.